Sign in or create an account to add this stock to your watchlist.
About Akcea Therapeutics (NASDAQ:AKCA)
Akcea Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing drugs to treat patients with cardiometabolic diseases caused by lipid disorders in the United States and internationally. It develops Volanesorsen, which has completed Phase 3 clinical study for the treatment of familial chylomicronemia syndrome; and that is in Phase 3 clinical study for the treatment of familial partial lipodystrophy. The company also develops AKCEA-APO(a)-LRx, which has completed Phase 2b clinical study for treating patients suffering with hyperlipoproteinemia; AKCEA-ANGPTL3-LRx that has completed Phase 1/2 clinical study for the treatment of multiple lipid disorders; and AKCEA-APOCIII-LRx, which is in Phase 1/2 study for the treatment of cardiovascular disease due to elevated triglyceride levels. It has strategic collaboration with Novartis Pharma AG. The company was incorporated in 2014 and is headquartered in Cambridge, Massachusetts. Akcea Therapeutics, Inc. is a subsidiary of Ionis Pharmaceuticals, Inc.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Trailing P/E Ratio-10.08
Forward P/E Ratio-12.40
Sales & Book Value
Annual Sales$55.21 million
Price / Sales34.99
Price / CashN/A
Book Value$1.71 per share
Price / Book13.20
EPS (Most Recent Fiscal Year)($2.24)
Return on Equity-75.90%
Return on Assets-27.67%
Akcea Therapeutics (NASDAQ:AKCA) Frequently Asked Questions
What is Akcea Therapeutics' stock symbol?
Akcea Therapeutics trades on the NASDAQ under the ticker symbol "AKCA."
How were Akcea Therapeutics' earnings last quarter?
Akcea Therapeutics (NASDAQ:AKCA) announced its quarterly earnings data on Thursday, May, 3rd. The company reported ($0.44) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.37) by $0.07. The firm earned $17.11 million during the quarter, compared to analyst estimates of $12.12 million. Akcea Therapeutics had a negative net margin of 126.00% and a negative return on equity of 75.90%. The business's revenue for the quarter was up 181.0% compared to the same quarter last year. View Akcea Therapeutics' Earnings History.
What price target have analysts set for AKCA?
4 brokers have issued 1-year price targets for Akcea Therapeutics' shares. Their forecasts range from $20.00 to $38.00. On average, they anticipate Akcea Therapeutics' share price to reach $29.3333 in the next twelve months. View Analyst Ratings for Akcea Therapeutics.
Who are some of Akcea Therapeutics' key competitors?
Some companies that are related to Akcea Therapeutics include Alkermes (ALKS), Sarepta Therapeutics (SRPT), Ionis Pharmaceuticals (IONS), Catalent (CTLT), GALAPAGOS NV/S (GLPG), Loxo Oncology (LOXO), Agios Pharmaceuticals (AGIO), Dr. Reddy's Laboratories (RDY), United Therapeutics (UTHR), Taro Pharmaceutical Industries (TARO), Hutchison China MediTech (HCM), FibroGen (FGEN), GW Pharmaceuticals (GWPH), Ligand Pharmaceuticals (LGND) and Blueprint Medicines (BPMC).
Who are Akcea Therapeutics' key executives?
Akcea Therapeutics' management team includes the folowing people:
- Ms. Paula Soteropoulos, CEO, Pres & Director (Age 50)
- Mr. Jeffrey M. Goldberg, Chief Operating Officer (Age 45)
- Dr. Louis St. Laurence O'Dea MB, BCh, BAO, FRCP(C), Chief Medical Officer, Exec. VP & Head of Regulatory Affairs (Age 67)
- Mr. Michael F. MacLean, Chief Financial Officer (Age 52)
- D. Wade Walke Ph.D., VP of Corp. Communications & Investor Relations
When did Akcea Therapeutics IPO?
(AKCA) raised $125 million in an initial public offering (IPO) on Friday, July 14th 2017. The company issued 9,600,000 shares at a price of $12.00-$14.00 per share. Cowen and Company, Stifel and Wells Fargo Securities acted as the underwriters for the IPO and BMO Capital Markets was co-manager.
Has Akcea Therapeutics been receiving favorable news coverage?
News headlines about AKCA stock have been trending somewhat positive recently, Accern Sentiment Analysis reports. Accern scores the sentiment of news coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Akcea Therapeutics earned a media sentiment score of 0.04 on Accern's scale. They also gave media stories about the company an impact score of 46.46 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the immediate future.
Who are Akcea Therapeutics' major shareholders?
Akcea Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional shareholders include IONIS PHARMACEUTICALS INC (75.00%), BB Biotech AG (3.58%), BlackRock Inc. (2.66%), Altrinsic Global Advisors LLC (0.22%), Eventide Asset Management LLC (0.20%) and Northern Trust Corp (0.26%). View Institutional Ownership Trends for Akcea Therapeutics.
Which major investors are selling Akcea Therapeutics stock?
AKCA stock was sold by a variety of institutional investors in the last quarter, including Eventide Asset Management LLC, BlackRock Inc., New York State Common Retirement Fund, Wells Fargo & Company MN, MetLife Investment Advisors LLC, JPMorgan Chase & Co. and Zurcher Kantonalbank Zurich Cantonalbank. View Insider Buying and Selling for Akcea Therapeutics.
Which major investors are buying Akcea Therapeutics stock?
AKCA stock was acquired by a variety of institutional investors in the last quarter, including BB Biotech AG, Bellevue Group AG, Altrinsic Global Advisors LLC, Jane Street Group LLC, Millennium Management LLC, Barclays PLC, Schwab Charles Investment Management Inc. and Cubist Systematic Strategies LLC. View Insider Buying and Selling for Akcea Therapeutics.
How do I buy shares of Akcea Therapeutics?
Shares of AKCA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Akcea Therapeutics' stock price today?
One share of AKCA stock can currently be purchased for approximately $22.57.
How big of a company is Akcea Therapeutics?
Akcea Therapeutics has a market capitalization of $1.87 billion and generates $55.21 million in revenue each year. The company earns $-109,750,000.00 in net income (profit) each year or ($2.24) on an earnings per share basis. Akcea Therapeutics employs 100 workers across the globe.
How can I contact Akcea Therapeutics?
Akcea Therapeutics' mailing address is 55 CAMBRIDGE PARKWAY SUITE 100, CAMBRIDGE MA, 92010. The company can be reached via phone at 617-207-0202 or via email at [email protected]
MarketBeat Community Rating for Akcea Therapeutics (AKCA)MarketBeat's community ratings are surveys of what our community members think about Akcea Therapeutics and other stocks. Vote "Outperform" if you believe AKCA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AKCA will underperform the S&P 500 over the long term. You may vote once every thirty days.
Akcea Therapeutics (NASDAQ:AKCA) Dividend History by Quarter
(Data available from 1/1/2013 forward)
|Announced||Period||Amount||Yield||Ex-Dividend Date||Record Date||Payable Date|
Akcea Therapeutics (NASDAQ AKCA) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 3.88%
Institutional Ownership Percentage: 23.96%
Akcea Therapeutics (NASDAQ AKCA) Insider Trading History
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|4/17/2018||Ionis Pharmaceuticals Inc||Major Shareholder||Buy||10,666,666||$18.75||$199,999,987.50||53,447,879|| |
|7/19/2017||Ionis Pharmaceuticals Inc||Major Shareholder||Buy||3,125,000||$8.00||$25,000,000.00||28,884,540|| |
Akcea Therapeutics (NASDAQ AKCA) News Headlines
Akcea Therapeutics (NASDAQ:AKCA) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Akcea Therapeutics (NASDAQ:AKCA) Income Statement, Balance Sheet and Cash Flow Statement
Akcea Therapeutics (NASDAQ AKCA) Stock Chart for Thursday, May, 24, 2018